SpringWorks Therapeutics, Inc.

NasdaqGS:SWTX Stok Raporu

Piyasa değeri: US$2.3b

SpringWorks Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

SpringWorks Therapeutics CEO'su Saqib Islam, Jul2018 tarihinde atandı, in görev süresi 6.33 yıldır. in toplam yıllık tazminatı $ 18.35M olup, şirket hissesi ve opsiyonları dahil olmak üzere 4% maaş ve 96% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.93% ine doğrudan sahiptir ve bu hisseler $ 21.23M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.5 yıl ve 5.3 yıldır.

Anahtar bilgiler

Saqib Islam

İcra Kurulu Başkanı

US$18.4m

Toplam tazminat

CEO maaş yüzdesi4.0%
CEO görev süresi6.3yrs
CEO sahipliği0.9%
Yönetim ortalama görev süresi4.5yrs
Yönetim Kurulu ortalama görev süresi5.3yrs

Son yönetim güncellemeleri

Recent updates

SpringWorks Therapeutics Merits A Speculative Buy

Nov 04

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Aug 07

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

May 11
Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

May 03
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

Apr 25

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

Apr 19

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Sep 20
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Jun 07
We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Feb 22
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

SpringWorks drops 21% as Allogene drops lead asset in combination study

Aug 10

SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15

Aug 04

Sizing Up SpringWorks Therapeutics

Jul 20

Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

Jun 06
Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

May 02

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

Dec 30
Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Dec 14

SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

Sep 15
SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

SpringWorks shows durable effect for neurofibroma therapy with long-term data

Jun 15

SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma

Jun 07

We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow

May 31
We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow

SpringWorks Therapeutics EPS misses by $0.11

May 06

CEO Tazminat Analizi

Saqib Islam'un ücretlendirmesi SpringWorks Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$301m

Mar 31 2024n/an/a

-US$339m

Dec 31 2023US$18mUS$725k

-US$325m

Sep 30 2023n/an/a

-US$305m

Jun 30 2023n/an/a

-US$298m

Mar 31 2023n/an/a

-US$289m

Dec 31 2022US$15mUS$680k

-US$277m

Sep 30 2022n/an/a

-US$259m

Jun 30 2022n/an/a

-US$228m

Mar 31 2022n/an/a

-US$206m

Dec 31 2021US$18mUS$590k

-US$174m

Sep 30 2021n/an/a

-US$107m

Jun 30 2021n/an/a

-US$87m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$8mUS$541k

-US$46m

Sep 30 2020n/an/a

-US$73m

Jun 30 2020n/an/a

-US$68m

Mar 31 2020n/an/a

-US$62m

Dec 31 2019US$3mUS$480k

-US$51m

Sep 30 2019n/an/a

-US$41m

Jun 30 2019n/an/a

-US$29m

Mar 31 2019n/an/a

-US$18m

Dec 31 2018US$2mUS$407k

-US$18m

Tazminat ve Piyasa: Saqib 'nin toplam tazminatı ($USD 18.35M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.64M ).

Tazminat ve Kazançlar: Saqib şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Saqib Islam (54 yo)

6.3yrs

Görev süresi

US$18,351,489

Tazminat

Mr. Saqib Islam, J.D. has been Chief Executive Officer and Director at SpringWorks Therapeutics, Inc. since August 2018. He serves as an Independent Director of Passage Bio, Inc. since March 2019. Mr. Isla...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Saqib Islam
CEO & Director6.3yrsUS$18.35m0.93%
$ 21.2m
Francis Perier
Chief Financial Officer5.3yrsUS$3.74m0.025%
$ 572.1k
Badreddin Edris
Chief Operating Officer3.8yrsUS$6.64m0.21%
$ 4.8m
James Cassidy
Chief Medical Officer3.3yrsUS$4.31m0.031%
$ 706.7k
Michael Nofi
Chief Accounting Officer4.7yrsVeri yok0.0083%
$ 188.7k
Tai-An Lin
Chief Scientific Officer1.2yrsVeri yok0.0075%
$ 171.4k
Kim Diamond
Vice President of Communications & Investor Relations6.8yrsVeri yokVeri yok
Herschel Weinstein
General Counsel & Secretary4.8yrsUS$2.83m0.018%
$ 417.3k
Daniel Pichl
Chief People Officer4.3yrsUS$2.52m0.0065%
$ 148.2k
Bhavesh Ashar
Chief Commercial Officer3.7yrsUS$4.94m0.014%
$ 314.1k

4.5yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: SWTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.5 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Saqib Islam
CEO & Director6.3yrsUS$18.35m0.93%
$ 21.2m
Alan Fuhrman
Independent Director5.3yrsUS$520.14k0.014%
$ 323.7k
Daniel Lynch
Independent Chairman of the Board8.8yrsUS$545.14k0.41%
$ 9.2m
Martin MacKay
Directorless than a yearVeri yokVeri yok
Freda Lewis-Hall
Independent Director7.3yrsUS$508.45k0.014%
$ 323.7k
Carlos Alban
Independent Director2.3yrsUS$507.64k0.011%
$ 245.0k
Julie Hambleton
Independent Director4.5yrsUS$520.14k0%
$ 0

5.3yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SWTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).